Off-target ACE2 ligands: Possible therapeutic option for CoVid-19?

Br J Clin Pharmacol. 2020 Jun;86(6):1178-1179. doi: 10.1111/bcp.14343. Epub 2020 May 13.

Authors

Simone Brogi¹, Vincenzo Calderone¹

Affiliation

¹ Department of Pharmacy, University of Pisa, Pisa, Italy.

No abstract available

Keywords: CoVid-19; SARS-Cov-2; betacoronavirus; human angiotensin-converting enzyme 2 (ACE2); repurposing.

Publication types

Letter

MeSH terms

Angiotensin-Converting Enzyme 2
Antiviral Agents / pharmacology*
COVID-19
Coronavirus Infections / drug therapy*
Coronavirus Infections / physiopathology
Coronavirus Infections / virology
Drug Design
Humans
Ligands
Molecular Targeted Therapy
Pandemics
Peptidyl-Dipeptidase A / metabolism*
Pneumonia, Viral / drug therapy*
Pneumonia, Viral / physiopathology
Pneumonia, Viral / virology

Substances

Antiviral Agents
Ligands
Peptidyl-Dipeptidase A
ACE2 protein, human
Angiotensin-Converting Enzyme 2